ArticleEuropean journal of nuclear medicine and molecular imaging2021
A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [
Article in European journal of nuclear medicine and molecular imaging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Global and regional amyloid-β in explaining APOE-ε4 and sex associations with medial temporal tau: a neuropathology study.Acta neuropathologica · 2026Article
- Quantitative agreement between AMYclz and CortexID forJapanese journal of radiology · 2026Article
- Association of global gray matter volume and cortical thickness with cognitive function stratified by amyloid PET status.Annals of nuclear medicine · 2026Article
- Comparability of Centiloid values from [Neuroimage. Reports · 2026Article
- Discordance in amyloid positivity between visual reads and Centiloids: Impact of white matter uptake.The journal of prevention of Alzheimer's disease · 2026Article
- Clinical amyloid and tau positron emission tomography imaging in Alzheimer's disease: image interpretation in the era of anti-amyloid therapies.Current opinion in neurology · 2026Review
- Long-term impact of disclosing amyloid PET results to individuals with subjective cognitive decline.Alzheimer's research & therapy · 2026Article
- The Alzheimer's Disease Diagnosis and Plasma Phospho-Tau217 (ADAPT) study stage 1: Validating clinical cut-points against CSF and amyloid PET.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Mapping Alzheimer's disease heterogeneity with molecular imaging biomarkers.European journal of clinical investigation · 2026Review
- Added Value of Amyloid PET Quantification with the Centiloid Scale in Clinical Practice.AJNR. American journal of neuroradiology · 2025Article
- Complementary utility of plasma biomarkers and Aβ-PET for diagnosis, risk-stratification, and treatment monitoring in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
- Concordance Between Amyloid-PET Quantification and Real-World Visual Reads.JAMA neurology · 2025Article
- Comparison of Amyloid-PET Analysis Software UsingDiagnostics (Basel, Switzerland) · 2025Article
- Comparison and cutoff values of two amyloid PET scaling methods: centiloid scale and amyloid-β load.Annals of nuclear medicine · 2025Article
- Cutoff SUVR of [Nuclear medicine and molecular imaging · 2025Article
- Decreased water exchange rate across the blood-brain barrier throughout the Alzheimer's disease continuum: Evidence from Chinese data.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Quantification Supports Amyloid PET Visual Assessment of Challenging Cases: Results from the AMYPAD Diagnostic and Patient Management Study.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Expert opinion on Centiloid thresholds suitable for initiating anti-amyloid therapy. Summary of discussion at the 2024 spring Alzheimer's Association Research Roundtable.The journal of prevention of Alzheimer's disease · 2025Article
- Experiences from Clinical Research and Routine Use of Florbetaben Amyloid PET-A Decade of Post-Authorization Insights.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Acceptable performance of blood biomarker tests of amyloid pathology - recommendations from the Global CEO Initiative on Alzheimer's Disease.Nature reviews. Neurology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
background[
methodsA total of 2770 [
resultsWeighted mean concordance between visual and quantitation using the autopsy-derived threshold was 94% using pons as the reference region. Concordance from a sensitivity analysis which assessed the maximum agreement for each cohort using a range of cut-off values was also estimated at approximately 96% (weighted mean). Agreement was generally higher in clinical cases compared to research cases. V-Q+ discordant cases were 11% more likely to progress to AD than V+Q- for the SUVr with pons as reference region.
conclusionsQuantitation of amyloid PET shows a high agreement vs binary visual reading and also allows for a continuous measure that, in conjunction with possible discordant analysis, could be used in the future to identify possible earlier pathological deposition as well as monitor disease progression and treatment effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.